[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovulation-induction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovulation-induction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100649087","oral-gnrh-antagonist-linzagolix-versus-injectable-gnrh-antagonist-and-progestin-primed-ovarian-stimulation-ppos-in-controlled-ovarian-stimulation-for-in-vitro-fertilization-a-prospective-comparative-observational-study-100649087",false,"NCT07732348","Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study","Inclusion Criteria:\n\n* Female, aged 18 to 42 years\n* Indication for IVF\u002FICSI with controlled ovarian stimulation at CENTRO AMBRA\n* Population unselected for ovarian reserve (normal, poor, and high responders are eligible)\n* Written informed consent, including consent for off-label use of linzagolix and for data processing\n* For the two antagonist arms (Linzagolix and Injectable GnRH Antagonist): acceptance of randomization\n\nExclusion Criteria:\n\n* Known contraindications or hypersensitivity to the study drugs\n* Uterine pathology relevant to the study outcome (e.g., uterine malformations, significant submucosal fibroids)\n* Contraindications to pregnancy or to ovarian stimulation\n* Concurrent participation in another interfering interventional study","FEMALE","18 Years","42 Years",{"count":19,"type":20},195,"ESTIMATED","OBSERVATIONAL","Preventing a premature rise in luteinizing hormone (LH) is essential during ovarian stimulation for in vitro fertilization (IVF), because such a rise can reduce the number of eggs collected. Current practice relies on either a daily injectable GnRH antagonist or an oral progestin (PPOS), which requires that all embryos be frozen.\n\nLinzagolix is an oral GnRH antagonist already approved for uterine fibroids and endometriosis. It has not previously been used to control ovarian stimulation for IVF; this study represents its first use for this purpose.\n\nThis is an observational study: participants are not randomly assigned to a treatment. Each woman receives one of three approaches - oral linzagolix, an injectable GnRH antagonist (ganirelix or cetrorelix), or PPOS - chosen by the clinical team based on her individual situation. The three groups are then compared using statistical adjustment for baseline differences between them.\n\nThe study will enroll approximately 195 women undergoing IVF or ICSI, aged 18 to \\[42\\], who are not selected based on ovarian reserve. All participants receive individualized gonadotropin stimulation and standard monitoring; only the method used to prevent premature ovulation differs by group.\n\nThe main question is whether linzagolix leads to a similar number of mature eggs (MII) retrieved compared with the injectable antagonist. The study will also assess how well each approach suppresses LH, safety (including ovarian hyperstimulation), and the number of injections needed.",[24,25],"Infertility, Female","Ovulation Induction",[27,28,29,30,31,32,33,34],"Oral GnRH Antagonist","Linzagolix","Controlled Ovarian Stimulation","In Vitro Fertilization","ICSI","Progestin-Primed Ovarian Stimulation","Oocyte Maturation","OHSS Prevention","NOT_YET_RECRUITING","2026-07-31",{"date":38,"type":39},"2026-08-03","ACTUAL",{"date":41,"type":20},"2026-09",{"date":43,"type":20},"2026-12",{"name":45,"class":46},"Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100587930","le--cc-vs-le-for-ovulation-induction-100587930","NCT06934785","LE + CC vs. LE for Ovulation Induction","The Combination of Letrozole (LE) and Clomiphene Citrate (CC) or LE Alone for Ovulation Induction in Women With WHO Group II\u002FIV Ovulatory Disorders: A Randomized Controlled Trial","COLA","Inclusion Criteria:\n\n* Women 18-40 years of age\n* Having ovulation disorder (length of cycle \\\u003C 21 or \\> 35 days or having \\\u003C 8 cycles per year)\n* FSH ≥5 IU\u002FL and ≤25 IU\u002FL, or LH ≥5 IU\u002FL and AMH ≥1.2 ng\u002FmL\n* Progressive motility (PR) ≥ 32% OR total progressive motility sperm count \\> 5 million; and sperm concentration ≥ 5 million\u002Fml, (World Health Organization, 2021)\n* Agreeing to take part in study.\n* Not participating in other studies.\n\nExclusion Criteria:\n\n* Untreated thyroid disease; Thyroid disease is suspected if patients have one of these (Bednarczuk et al., 2021); TSH ≥4 mIU\u002FL or TSH ≥2.5mIU\u002FL and TPOAb (+) or TSH \\\u003C0.1mIU\u002FL\n* Untreated hyper-prolactinemia; Hyperprolactinemia is suspected if patients have prolactinemia concentration \\>50 ng\u002FmL (The sample is collected after an overnight fast, at least 2 hours after waking up, ensuring that venipuncture does not cause excessive stress.)\n* Allergy or having contraindications to LE or CC;\n* Unilateral or Bilateral fallopian tube blockage (HSG, HyFoSy or surgery confirmation)\n* Untreated endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, or chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2; severe adenomyosis; congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate.","40 Years",{"count":57,"type":20},600,"INTERVENTIONAL",[60],"NA","This randomized controlled trial (RCT) aims to evaluate whether, in infertile women with WHO II\u002FIV ovulatory disorders, a combination of letrozole (LE) and clomiphene citrate (CC) compared to LE alone, result in higher live birth rates.\n\nThe study is designed as an open-label, multicenter RCT across six fertility clinics in Vietnam. Participants will be randomized into two groups: (1) LE + CC , (2) LE alone. The primary outcome measure is the live birth rate after one treatment cycle. Based on prior data, the live birth rate for IUI in letrozole cycles is estimated at 12%. To detect a 10% increase in live birth rates with CC, 436 couples are needed (α = 0.05, power = 80%). Additionally, the live birth rate after IUI with LE-induced ovulation is approximately 18.7% (Diamond et al., 2015). To detect a 10% increase with CC, 560 couples are required (α = 0.05, power = 80%). Considering a 5% loss to follow-up and protocol deviations, the study plans to recruit 600 participants (150 per arm).",[63,64,65,25],"Letrozole","Clomiphene Citrate","Ovulation Disorder","RECRUITING","2026-07-17",{"date":69,"type":39},"2026-07-21",{"date":71,"type":39},"2025-04-28",{"date":73,"type":20},"2027-06-30",{"name":75,"class":46},"Mỹ Đức Hospital",1]